Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Payables (2016 - 2025)

Historic Payables for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $18.4 million.

  • Agios Pharmaceuticals' Payables rose 1028.66% to $18.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $18.4 million, marking a year-over-year increase of 1028.66%. This contributed to the annual value of $18.4 million for FY2025, which is 1028.66% up from last year.
  • Agios Pharmaceuticals' Payables amounted to $18.4 million in Q4 2025, which was up 1028.66% from $19.6 million recorded in Q3 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Payables peaked at $51.2 million during Q1 2021, and registered a low of $7.7 million during Q2 2021.
  • Its 5-year average for Payables is $15.1 million, with a median of $12.4 million in 2023.
  • Its Payables has fluctuated over the past 5 years, first surged by 17382.26% in 2021, then plummeted by 7745.0% in 2022.
  • Agios Pharmaceuticals' Payables (Quarter) stood at $16.7 million in 2021, then increased by 11.47% to $18.6 million in 2022, then crashed by 47.46% to $9.8 million in 2023, then surged by 70.17% to $16.6 million in 2024, then grew by 10.29% to $18.4 million in 2025.
  • Its Payables stands at $18.4 million for Q4 2025, versus $19.6 million for Q3 2025 and $17.5 million for Q2 2025.